Vise Technologies Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Vise Technologies acquired 7,882 Vertex shares in the second quarter, valued at approximately $3.9 million. Institutional investors collectively own 90.96% of the company.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and a $563.50 target price; recent targets include $595 from Cantor Fitzgerald and $585 from UBS.
• Vertex reported quarterly revenue of $3.33 billion, up 12.5% year over year and above estimates, although earnings of $4.73 per share narrowly missed consensus. Insiders sold 10,464 shares worth nearly $5 million during the quarter.

Vise Technologies Inc. acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,882 shares of the pharmaceutical company's stock, valued at approximately $3,915,000.

A number of other hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at $11,975,849,000. Norges Bank acquired a new position in Vertex Pharmaceuticals in the 4th quarter worth $1,440,149,000. AIGH Capital Management LLC acquired a new position in Vertex Pharmaceuticals in the 2nd quarter worth $26,725,000. Bank of New York Mellon Corp purchased a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $830,842,000. Finally, Deutsche Bank AG purchased a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $784,391,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 1,500 shares of the company's stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total transaction of $787,485.00. Following the completion of the transaction, the executive vice president owned 45,321 shares in the company, valued at approximately $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan Mckechnie sold 1,541 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the sale, the executive vice president directly owned 11,001 shares in the company, valued at approximately $5,709,519. This trade represents a 12.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 10,464 shares of company stock worth $4,959,397. Insiders own 0.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on VRTX shares. Cantor Fitzgerald lifted their target price on Vertex Pharmaceuticals from $590.00 to $595.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 4th. Sanford C. Bernstein raised Vertex Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, July 29th. Stifel Nicolaus set a $500.00 price objective on Vertex Pharmaceuticals in a research note on Tuesday, August 4th. Wall Street Zen downgraded Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, June 28th. Finally, UBS Group increased their target price on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a "buy" rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $563.50.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex completed the Phase 2b trial of inaxaplin, its treatment candidate for APOL1-mediated kidney disease. The milestone advances a potentially important non-cystic-fibrosis growth driver and could support future regulatory and commercialization plans. Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial
• Positive Sentiment: Wall Street remains optimistic about VRTX, with BMO Capital reiterating a Buy rating. Analysts point to Vertex’s leadership in cystic fibrosis and potential contributions from newer products and pipeline programs. Vertex Pharmaceuticals Receives a Buy from BMO Capital
• Positive Sentiment: Recent commentary describes cystic fibrosis as a continuing “engine” for Vertex’s rally, suggesting investors expect durable cash generation and additional growth from the company’s dominant franchise. Vertex Pharmaceuticals’ Rally Has a New Engine — and Wall Street Thinks the Best Is Still Ahead
• Neutral Sentiment: Vertex is reportedly entering a new healthcare focus, indicating a broader strategic emphasis beyond its established cystic fibrosis business. The longer-term impact will depend on the specific programs, investment requirements, and commercial potential. Vertex Pharmaceuticals Enters New Healthcare Focus
• Negative Sentiment: Shareholder challenges to Vertex’s proposed acquisition of Crinetics Pharmaceuticals create execution and deal-completion risk. Delays, litigation, or a higher acquisition cost could weigh on sentiment, even though the transaction is intended to expand Vertex’s pipeline. Crinetics Faces Shareholder Challenges to Vertex Merger Deal

Vertex Pharmaceuticals Trading Down 2.1%

Shares of Vertex Pharmaceuticals stock opened at $540.26 on Friday. The stock has a market capitalization of $137.12 billion, a price-to-earnings ratio of 31.45, a PEG ratio of 2.28 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a twelve month low of $374.17 and a twelve month high of $553.69. The business's 50 day simple moving average is $490.59 and its 200-day simple moving average is $465.35.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The company had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the firm earned $4.52 EPS. The company's revenue for the quarter was up 12.5% compared to the same quarter last year. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.86 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source